Ashlock MA - Search Results

1

Fluorescent chloride indicators to assess the efficacy of CFTR cDNA delivery.

Mansoura MK, Biwersi J, Ashlock MA, Verkman AS. Mansoura MK, et al. Among authors: ashlock ma. Hum Gene Ther. 1999 Apr 10;10(6):861-75. doi: 10.1089/10430349950018274. Hum Gene Ther. 1999. PMID: 10223721 Review.

2

An improved method for routine preparation of intact artificial chromosome DNA (340-1000 kb) for transfection into human cells.

Compton ST, Henning KA, Chen M, Mansoura MK, Ashlock MA. Compton ST, et al. Among authors: ashlock ma. Nucleic Acids Res. 1999 Apr 1;27(7):1762-5. doi: 10.1093/nar/27.7.1762. Nucleic Acids Res. 1999. PMID: 10076009 Free PMC article.

3

Transient gene expression from yeast artificial chromosome DNA in mammalian cells is enhanced by adenovirus.

Chen M, Compton ST, Coviello VF, Green ED, Ashlock MA. Chen M, et al. Among authors: ashlock ma. Nucleic Acids Res. 1997 Nov 1;25(21):4416-8. doi: 10.1093/nar/25.21.4416. Nucleic Acids Res. 1997. PMID: 9336477 Free PMC article.

4

cis-Acting elements within CFTR 5'-flanking DNA are not sufficient to decrease gene expression in response to phorbol ester.

Mogayzel PJ Jr, Esmail M, Wagner TL, Zeitlin PL, Ashlock M. Mogayzel PJ Jr, et al. Biochim Biophys Acta. 2002 Jul 19;1576(3):306-15. doi: 10.1016/s0167-4781(02)00395-0. Biochim Biophys Acta. 2002. PMID: 12084577

5

Isolation of human transcripts expressed in hamster cells from YACs by cDNA representational difference analysis.

Gu J, Guan XY, Ashlock MA. Gu J, et al. Among authors: ashlock ma. Genome Res. 1999 Feb;9(2):182-8. Genome Res. 1999. PMID: 10022983 Free PMC article.

6

Therapeutics development for cystic fibrosis: a successful model for a multisystem genetic disease.

Ashlock MA, Olson ER. Ashlock MA, et al. Annu Rev Med. 2011;62:107-25. doi: 10.1146/annurev-med-061509-131034. Annu Rev Med. 2011. PMID: 21226613 Review.

7

Introduction to Section I: the relevance of CF diagnostic tools for measuring restoration of CFTR function after therapeutic interventions in human clinical trials.

De Boeck K, Ashlock M. De Boeck K, et al. Methods Mol Biol. 2011;741:3-11. doi: 10.1007/978-1-61779-117-8_1. Methods Mol Biol. 2011. PMID: 21594774

8

Cystic fibrosis foundation: achieving the mission.

Marshall BC, Penland CM, Hazle L, Ashlock M, Wetmore D, Campbell PW 3rd, Beall RJ. Marshall BC, et al. Respir Care. 2009 Jun;54(6):788-95; discussion 795. doi: 10.4187/002013209790983223. Respir Care. 2009. PMID: 19467165 Free article. Review.

9

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.

Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu PA. Van Goor F, et al. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18843-8. doi: 10.1073/pnas.1105787108. Epub 2011 Oct 5. Proc Natl Acad Sci U S A. 2011. PMID: 21976485 Free PMC article.

10

CFTR intron 1 increases luciferase expression driven by CFTR 5'-flanking DNA in a yeast artificial chromosome.

Mogayzel PJ Jr, Ashlock MA. Mogayzel PJ Jr, et al. Among authors: ashlock ma. Genomics. 2000 Mar 1;64(2):211-5. doi: 10.1006/geno.2000.6119. Genomics. 2000. PMID: 10729228 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters